JDRF-funded researchers have developed a formulation of liquid glucagon that remains stable and viable for long periods of time and thus may be usable in standard diabetes pumps. The research represents advancement toward the routine delivery of glucagon for people with T1D and may also facilitate the development of bihormonal closed-loop artificial pancreas systems.
JDRF executives and 110 JDRF donors gathered in sunny St. Petersburg, FL, on May 1 and 2 for the JDRF Research Summit: Transforming JDRF. Attendees, including generous donors and dedicated volunteers from Florida and the surrounding states—as well as some from as far away as California—received a “crash course” in exactly what’s happening in the [...]
The Special Diabetes Program (SDP) of the National Institutes of Health was established in 1997. The SDP is a key component of the federal government’s commitment to type 1 diabetes (T1D) research. There are two parts of the program: the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians. In the [...]
By Michelle A. Cissell, Ph.D. In 2007, JDRF took a calculated risk by creating the Network for Pancreatic Organ Donors with Diabetes (nPOD) to collect and distribute pancreatic and other tissues from deceased organ donors with type 1 diabetes (T1D), as well as from those without the disease but with multiple antibodies indicating high [...]
JDRF-supported researchers have found that dysfunction of pancreatic beta cells precedes the onset of T1D in a mouse model of the disease. The study is the first direct demonstration that ER stress happens before the onset of T1D in an animal model. These findings help illuminate the earliest stages of T1D, and suggest that alleviating ER stress with drugs or other therapeutics might provide an avenue for slowing progression and onset of disease.
JDRF has partnered with San Diego–based medical company Dexcom, Inc. to support the manufacture of a so-called smart transmitter prototype, which will be available for research purposes before it will be commercially available. The technological advance not only would reduce the number of devices a person would have to wear with an artificial pancreas system, but would also enable wireless connectivity among these devices—an important feature that would give people with T1D the freedom of movement while participating in real-life outpatient studies.
JDRF and the Canadian government are expanding the Adolescent Type 1 Diabetes Cardio-Renal (heart and kidney) Intervention Trial (AdDIT) by adding one additional clinical site in southern Ontario, Canada. The expansion will serve to accelerate the recruitment of adolescents with type 1 diabetes (T1D) and microalbuminuria, a condition in which a protein called albumin leaks into the urine—a sign of early kidney disease and a risk factor for developing heart disease later in life.
In one of the largest studies of its kind, JDRF has partnered with iCo Therapeutics to investigate a potential new drug that could, if successful, broaden treatment options for people living with DME. The Phase II trial, led and coordinated by Johns Hopkins University investigators, is currently recruiting participants. To inquire about participation, please contact Dr. Quan Dong Nguyen or click here.
You could call them brothers-in-arms in the battle against type 1 diabetes (T1D): Maarten de Groot, founder and president of JDRF Netherlands, our organization’s newest international affiliate; and Bart Roep, M.D., Ph.D., a clinical immunologist who leads a T1D research team at Leiden University Medical Center, in the Netherlands. Dr. Roep is one of the [...]
There’s no end to what you can learn when visiting our nation’s capital. On February 18, more than 600 people, all sharing a connection to type 1 diabetes (T1D), attended the 2012 JDRF Type 1 Diabetes Research Summit hosted by the JDRF Capitol Chapter. A letter in the summit program from United States Senator Jeanne [...]